Chronic periaortitis (CP) is a rare condition, hallmarked by periaortic fi bro-infl ammatory tissue which often causes ureteral obstruction, and encompasses idiopathic retroperitoneal fi brosis and infl ammatory abdominal aortic aneurysm (IAAA). CP usually responds to glucocorticoids, but some patients may be steroid-refractory or not tolerate standard glucocorticoid doses. For such cases, valid therapeutic alternatives are lacking. Combinations of prednisone and immunosuppressants (eg, cyclophosphamide, mycophenolate mofetil) are not of proven superiority to prednisone alone, and their effectiveness in refractory CP is unknown. Because B cells abundantly infi ltrate CP lesions, and CP is often associated with autoimmune diseases, we used rituximab in two patients with CP, one refractory to conventional treatments, and the other with contraindications to standard-dose glucocorticoids.

Rituximab therapy for chronic periaortitis / Maritati F.; Corradi D.; Versari A.; Casali M.; Urban M.L.; Buzio C.; Vaglio A.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - ELETTRONICO. - 71:(2012), pp. 1262-1264. [10.1136/annrheumdis-2011-201166]

Rituximab therapy for chronic periaortitis

Corradi D.;Urban M. L.;Vaglio A.
2012

Abstract

Chronic periaortitis (CP) is a rare condition, hallmarked by periaortic fi bro-infl ammatory tissue which often causes ureteral obstruction, and encompasses idiopathic retroperitoneal fi brosis and infl ammatory abdominal aortic aneurysm (IAAA). CP usually responds to glucocorticoids, but some patients may be steroid-refractory or not tolerate standard glucocorticoid doses. For such cases, valid therapeutic alternatives are lacking. Combinations of prednisone and immunosuppressants (eg, cyclophosphamide, mycophenolate mofetil) are not of proven superiority to prednisone alone, and their effectiveness in refractory CP is unknown. Because B cells abundantly infi ltrate CP lesions, and CP is often associated with autoimmune diseases, we used rituximab in two patients with CP, one refractory to conventional treatments, and the other with contraindications to standard-dose glucocorticoids.
2012
71
1262
1264
Goal 3: Good health and well-being for people
Maritati F.; Corradi D.; Versari A.; Casali M.; Urban M.L.; Buzio C.; Vaglio A.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1197656
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 46
social impact